[go: up one dir, main page]

BR9814055A - Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto - Google Patents

Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto

Info

Publication number
BR9814055A
BR9814055A BR9814055-8A BR9814055A BR9814055A BR 9814055 A BR9814055 A BR 9814055A BR 9814055 A BR9814055 A BR 9814055A BR 9814055 A BR9814055 A BR 9814055A
Authority
BR
Brazil
Prior art keywords
compound
processes
pharmaceutical composition
allergic disease
alkyl
Prior art date
Application number
BR9814055-8A
Other languages
English (en)
Other versions
BR9814055B1 (pt
Inventor
Yasuo Ohtsuka
Toshio Nishizuka
Sohjiro Shiokawa
Seiji Tsutsumi
Mami Kawaguchi
Hideo Kitagawa
Hiromi Takata
Takashi Shishikura
Toyoaki Ishikura
Kenichi Fushihara
Yumiko Okada
Sachiko Miyamoto
Maki Shiobara
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BR9814055A publication Critical patent/BR9814055A/pt
Publication of BR9814055B1 publication Critical patent/BR9814055B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA O TRATAMENTO DE UMA DOENçA ALéRGICA, USO DO COMPOSTO, E, PROCESSOS PARA PREPARAR E PARA PRODUZIR UM COMPOSTO" Derivados de triazolbenzazepina tricíclicos sob a forma de uma pró-droga são providos. Os compostos de acordo com a presente invenção são aqueles representados pela fórmula (I) e solvatos e sais farmacologicamente aceitáveis dos mesmos. Os compostos são úteis como agentes antialérgicos e exibem excelente biodisponibilidade. em que R^ 1^ representa hidrogênio, OH, alquila ou fenil alquila, R^ 2^, R^ 3^, R^ 4^ e R^ 5^ representam hidrogênio, halogênio, hidroxila opcionalmente protegida, formila, alquila opcionalmente protegida, alquenila, alcoxi ou os similares, e Q representa um grupo selecionado a partir dos seguintes grupos (i) a (iv), halogênio ou alcoxi:
BRPI9814055-8A 1997-09-29 1998-09-29 composto, composição farmacêutica, uso do composto, e, processos para preparar e para produzir um composto. BR9814055B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26461197 1997-09-29
JP5206398 1998-03-04
PCT/JP1998/004363 WO1999016770A1 (en) 1997-09-29 1998-09-29 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic

Publications (2)

Publication Number Publication Date
BR9814055A true BR9814055A (pt) 2000-09-26
BR9814055B1 BR9814055B1 (pt) 2009-05-05

Family

ID=26392670

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9814055-8A BR9814055B1 (pt) 1997-09-29 1998-09-29 composto, composição farmacêutica, uso do composto, e, processos para preparar e para produzir um composto.

Country Status (24)

Country Link
US (3) US6372735B1 (pt)
EP (1) EP1026167B1 (pt)
JP (1) JP3188482B2 (pt)
KR (1) KR100389140B1 (pt)
CN (2) CN1312135C (pt)
AT (1) ATE233764T1 (pt)
AU (1) AU744636B2 (pt)
BR (1) BR9814055B1 (pt)
CA (1) CA2305307C (pt)
DE (1) DE69811930T2 (pt)
DK (1) DK1026167T3 (pt)
ES (1) ES2191963T3 (pt)
HU (1) HUP0004020A3 (pt)
ID (1) ID24101A (pt)
IL (1) IL135303A0 (pt)
NO (2) NO319542B1 (pt)
NZ (1) NZ503601A (pt)
PL (1) PL339544A1 (pt)
PT (1) PT1026167E (pt)
RU (1) RU2198885C2 (pt)
SK (1) SK283869B6 (pt)
TR (1) TR200000808T2 (pt)
TW (1) TW510902B (pt)
WO (1) WO1999016770A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055886A1 (en) * 2001-12-26 2003-07-10 Meiji Seika Kaisha, Ltd. Amorphous substance of tricyclic triazolobenzazepine derivative
US7238719B2 (en) * 2002-02-01 2007-07-03 Meiji Seika Kaisha, Ltd. Process for producing 1,2,3-Triazole compounds
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
HRP20050001A2 (en) 2002-07-09 2005-08-31 Bristol-Myers Squibb Company A Delaware (Usa) Corp Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20070167432A1 (en) * 2003-06-19 2007-07-19 Meiji Seila Kaisha, Ltd Tricyclic triazolobenzapine derivative produced as novel crystalline substance
JPWO2004113451A1 (ja) * 2003-06-20 2006-08-17 明治製菓株式会社 難溶性物質と水溶性高分子との共沈物およびその製造方法
US7572784B2 (en) 2004-05-14 2009-08-11 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
JPWO2007100079A1 (ja) * 2006-03-02 2009-07-23 明治製菓株式会社 三環性トリアゾロベンゾアゼピン誘導体を含有する、アレルギー性眼疾患またはアレルギー性鼻疾患の予防または治療剤
WO2008040332A1 (de) * 2006-09-25 2008-04-10 Forschungsverbund Berlin E.V. Strukturmimetika prolinreicher peptide und ihre pharmazeutische verwendung
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0821302A8 (pt) * 2007-12-18 2015-12-08 Meiji Seika Kaisha Composição farmacêutica, método para prevenir ou tratar doenças do intestino inflamatórias, e, uso de um composto
AU2009330727B2 (en) 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
WO2011084848A2 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs of heteraromatic compounds
CN104031049A (zh) 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CN117069712A (zh) * 2017-12-29 2023-11-17 生物马林药物股份有限公司 用于疾病治疗的乙醇酸氧化酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646570B1 (en) 1993-04-16 1998-06-24 Shionogi & Co., Ltd. Process for producing lignan compound
EP0686636B1 (en) * 1993-12-28 2001-04-04 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives
KR100286494B1 (ko) * 1995-06-15 2001-04-16 이치로 키타사토 삼환성벤즈아제핀화합물
AU723860B2 (en) * 1996-03-08 2000-09-07 Astrazeneca Ab Azolobenzazepine derivatives as neurologically active agents
US20070059533A1 (en) * 2005-09-12 2007-03-15 Burdette Steven R Thermal reflow of glass and fused silica body

Also Published As

Publication number Publication date
NO20001500L (no) 2000-05-18
JP3188482B2 (ja) 2001-07-16
AU744636B2 (en) 2002-02-28
CN1312135C (zh) 2007-04-25
AU9186998A (en) 1999-04-23
CN1155599C (zh) 2004-06-30
SK4252000A3 (en) 2000-10-09
US7022860B2 (en) 2006-04-04
NO319542B1 (no) 2005-08-29
RU2198885C2 (ru) 2003-02-20
NO20001500D0 (no) 2000-03-23
US20060074074A1 (en) 2006-04-06
US20020137739A1 (en) 2002-09-26
US6372735B1 (en) 2002-04-16
CN1278262A (zh) 2000-12-27
DK1026167T3 (da) 2003-05-26
NO20043765L (no) 2000-05-18
ID24101A (id) 2000-07-06
DE69811930T2 (de) 2003-12-18
ATE233764T1 (de) 2003-03-15
KR100389140B1 (ko) 2003-06-25
TR200000808T2 (tr) 2000-08-21
EP1026167B1 (en) 2003-03-05
EP1026167A4 (en) 2001-07-11
IL135303A0 (en) 2001-05-20
HUP0004020A3 (en) 2002-12-28
SK283869B6 (sk) 2004-03-02
NZ503601A (en) 2002-02-01
ES2191963T3 (es) 2003-09-16
CN1523019A (zh) 2004-08-25
WO1999016770A1 (en) 1999-04-08
EP1026167A1 (en) 2000-08-09
BR9814055B1 (pt) 2009-05-05
DE69811930D1 (de) 2003-04-10
HUP0004020A2 (hu) 2001-09-28
TW510902B (en) 2002-11-21
PL339544A1 (en) 2000-12-18
HK1032782A1 (en) 2002-08-30
CA2305307A1 (en) 1999-04-08
KR20010030784A (ko) 2001-04-16
CA2305307C (en) 2004-11-30
PT1026167E (pt) 2003-07-31
US7238812B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
BR9814055A (pt) Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0112224A (pt) Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
BR0312280A (pt) Composto ou um sal, solvato, solvato de tal sal ou uma prodroga do mesmo faarmaceuticamente aceitável, processo para prepará-lo, composição farmacêutica, uso do composto, métodos para produzir um efeito inibidor da absorção de colesterol, e para tratar condições hiperlipidêmicas em um animal de sangue quente, tal como o homem, que necessita de tal tratamento, combinação, e, uso desta
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR0308056A (pt) Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
PT92378A (pt) Processo para a preparacao de derivados de cromano, activos sobre o sistema nervoso central
EE200000472A (et) Kasvajavastased toimeained
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
PT992509E (pt) Novos derivados macrolidos
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BRPI0408204A (pt) derivados de quinolinona/benzoxazinona e usos dos mesmos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0004823A (pt) Compostos policìclicos de azaindol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR0112122A (pt) Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto
BR0108840A (pt) Composto, prodroga, processo para produzir um composto, composição farmacêutica, método para prevenir ou tratar doenças inflamatórias, e, uso de um composto
BR0201312A (pt) Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos
BR0317244A (pt) Derivados de piperazina contendo fósforo como antagonistas ccr1
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin
DE69905524D1 (de) 8H-(2,3-b)-Pyrrolozin-8-one Derivate, Verfahren zur ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07D 487/04, C07F 9/6561, A61K 31/55, C07D 249/04, C07C 69/738, C07C 59/76, A61P 37/08

Ipc: C07D 487/04 (2007.01), C07F 9/6561 (2007.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: MEIJI SEIKA PHARMA CO., LTD. (JP)

Free format text: NOME ALTERADO DE: MEIJI SEIKA KAISHA, LTD.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2325 DE 28-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.